I cant speak for the other greedy mfers, but for m
Post# of 148279
The first is that it creates the possibility that the acquiring company doesnt release Leronlimab for some or all indications. I do not want this drug to be shelved.
The second is that a buyout, by definition is a discounted price due to the elimination of risk.
With that said I would entertain buyout offers if it was a reasonable price and with a company that doesnt have competing products that would encourage them to shelve it.